EXAS · As filed with the SEC
Exact Sciences balance sheet, by fiscal year
The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD thousands
| USD thousands | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2021 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | 955,996 | 600,889 | 605,378 | 242,493 |
| Marketable securities | 8,715 | 437,137 | 172,266 | 389,564 |
| Accounts receivable, net | 298,653 | 248,968 | 203,623 | 158,043 |
| Inventory | 166,201 | 162,383 | 127,475 | 118,259 |
| Prepaid expenses and other current assets | 126,284 | 122,046 | 85,627 | 73,898 |
| Total current assets | 1,555,849 | 1,571,423 | 1,194,369 | 982,257 |
| Long-term assets: | ||||
| Property, plant and equipment, net | 708,664 | 693,673 | 698,354 | 684,756 |
| Operating lease right-of-use assets | 122,332 | 116,952 | 143,708 | 167,003 |
| Goodwill | 2,368,048 | 2,366,676 | 2,367,120 | 2,346,040 |
| Intangible assets, net | 919,925 | 1,009,693 | 1,890,396 | 1,956,240 |
| Other long-term assets, net | 185,811 | 169,722 | 177,387 | 90,577 |
| Total assets | 5,860,629 | 5,928,139 | 6,471,334 | 6,226,873 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | 175,868 | 89,572 | 78,816 | 74,916 |
| Accrued liabilities | 416,473 | 328,292 | 341,683 | 299,216 |
| Operating lease liabilities, current portion | 33,591 | 27,405 | 29,379 | 28,366 |
| Other current liabilities | 15,220 | 37,765 | 14,823 | 10,249 |
| Loans Payable, Current | — | 0 | 50,000 | — |
| Convertible Notes Payable, Current | 0 | 249,153 | — | — |
| Total current liabilities | 641,152 | 732,187 | 514,701 | 412,747 |
| Convertible notes, net, less current portion | 2,327,177 | 2,321,067 | 2,314,276 | 2,186,106 |
| Long-term debt, less current portion | — | — | 0 | 50,000 |
| Other long-term liabilities | 329,317 | 315,503 | 335,982 | 352,459 |
| Operating lease liabilities, less current portion | 161,931 | 157,133 | 161,070 | 182,399 |
| Total liabilities | 3,459,577 | 3,525,890 | 3,326,029 | 3,183,711 |
| Stockholders’ equity: | ||||
| Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—190,802,322 and 185,616,438 shares at December 31, 2025 and December 31, 2024 | 1,909 | 1,857 | 1,815 | 1,780 |
| Additional paid-in capital | 7,102,766 | 6,899,368 | 6,611,237 | 6,311,644 |
| Accumulated other comprehensive income (loss) | 2,358 | (944) | 1,428 | (5,236) |
| Accumulated deficit | (4,705,981) | (4,498,032) | (3,469,175) | (3,265,026) |
| Total stockholders’ equity | 2,401,052 | 2,402,249 | 3,145,305 | 3,043,162 |
| Total liabilities and stockholders’ equity | 5,860,629 | 5,928,139 | 6,471,334 | 6,226,873 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.